{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   increases   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">Ciclosporin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ciclosporin   is predicted to   increase   the exposure to   tenofovir alafenamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   increases   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   tenofovir alafenamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eltrombopag</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fostemsavir\" outputclass=\"int-drug\">Fostemsavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fostemsavir   is predicted to   increase   the exposure to   tenofovir alafenamide .  Manufacturer advises adjust dose—consult product literature .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fostemsavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020660",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020660_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">Leflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Leflunomide   is predicted to   increase   the exposure to   tenofovir alafenamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020661",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020661_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   increases   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020662",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020662_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"oxcarbazepine\" outputclass=\"int-drug\">Oxcarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oxcarbazepine   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxcarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020663",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020663_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020664",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020664_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020665",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020665_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020666",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020666_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifabutin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020667",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020667_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020668",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020668_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020669",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020669_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">Teriflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Teriflunomide   is predicted to   increase   the exposure to   tenofovir alafenamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020670",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2#bnf_i1643858020670_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-heading-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				}
			],
			"hasSearchLabel": " Tenofovir alafenamide  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/tenofovir-alafenamide-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Tenofovir alafenamide </title>"
			},
			"rdfs:label": "tenofovir alafenamide"
		}
	]
}